PYC Therapeutics Limited Share Price
Stocks
PYC
AU000000PYC7
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.555 AUD | +1.97% |
|
+1.30% | -6.04% |
| 07-08 | PYC Therapeutics Says US Patent Office Grants Composition of Matter Patents for Three Drug Candidates | MT |
| 07-07 | PYC Therapeutics Names CFO | MT |
| Market Cap | 1.5B 1.04B 911M 840M 777M 1.48B 99.39B 10.06B 3.94B 48.81B 3.91B 3.82B 169B | P/E 2026 * |
-21.4x | P/E 2027 * | -15.7x |
|---|---|---|---|---|---|
| Enterprise Value | 832M 578M 506M 466M 431M 819M 55.16B 5.58B 2.19B 27.09B 2.17B 2.12B 93.83B | EV / Sales 2026 * |
227x | EV / Sales 2027 * | - |
| Free-Float |
70.64% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PYC Therapeutics Limited
| 03-16 | Bell Potter rates PYC as Speculative Buy | AQ |
| 09/09/25 | Bell Potter rates PYC as Speculative Buy | AQ |
| 07/11/24 | PYC Therapeutics : Anti Bribery & Anti Corruption Policy | PU |
| 07/11/24 | PYC Therapeutics : Definition of Independence | PU |
| 07/11/24 | PYC Therapeutics : Continuous Disclosure Policy | PU |
| 1 day | +1.97% | ||
| 1 week | +1.30% | ||
| Current month | -7.72% | ||
| 1 month | +34.05% | ||
| 3 months | +32.34% | ||
| 6 months | -5.18% | ||
| Current year | -6.04% |
| 1 week | 1.49 |  | 1.6 |
| 1 month | 1.14 | | 1.76 |
| Current year | 1.04 | | 1.76 |
| 1 year | 0.85 | | 1.76 |
| 3 years | 0.52 | | 2.1 |
| 5 years | 0.5 | | 2.1 |
| 10 years | 0.12 | | 2.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Rohan Hockings
CEO | Chief Executive Officer | 42 | 18/08/2020 |
Thomas Ulmer
DFI | Director of Finance/CFO | 47 | 06/07/2026 |
Paula Cunningham
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Coleman
CHM | Chairman | 66 | 17/11/2025 |
Rohan Hockings
BRD | Director/Board Member | 42 | 29/11/2018 |
Ian Constable
BRD | Director/Board Member | - | 21/09/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 03-26 | Buy | Chief Executive Officer | 82,550 | 0.0085% | ||
| 03-09 | Buy | Chief Executive Officer | 80,010 | 0.0082% | ||
| 12-22 | Free | Chairman | 2,000,000 | 0.3429% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.97% | +1.30% | +7.99% | +139.23% | 1.04B | |
| +1.68% | +3.19% | +3.55% | +10.97% | 50.44B | |
| +0.72% | +1.00% | +396.18% | +624.25% | 40.63B | |
| +2.54% | +0.93% | +28.98% | -3.62% | 34.88B | |
| +0.31% | +1.74% | +18.44% | +59.76% | 33.67B | |
| -2.09% | -1.98% | +3.21% | +33.56% | 26.29B | |
| -0.63% | +0.34% | - | - | 17.11B | |
| +0.66% | -3.96% | +66.85% | +127.36% | 15.29B | |
| -23.90% | -21.43% | +50.06% | +53.83% | 10.62B | |
| +2.59% | -0.49% | +15.24% | +21.25% | 13.74B | |
| Average | -1.61% | -3.00% | +65.61% | +118.51% | 24.37B | |
| Weighted average by Cap. | -0.24% | -0.63% | +87.22% | +139.64% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.67M 2.55M 2.23M 2.05M 1.9M 3.61M 243M 24.59M 9.64M 119M 9.56M 9.35M 413M | - |
| Net income | -61.32M -42.57M -37.24M -34.34M -31.77M -60.31M -4.06B -411M -161M -2B -160M -156M -6.91B | -91.46M -63.5M -55.55M -51.22M -47.4M -89.96M -6.06B -613M -240M -2.98B -238M -233M -10.31B |
| Net Debt | -667M -463M -405M -374M -346M -656M -44.23B -4.48B -1.75B -21.72B -1.74B -1.7B -75.23B | -584M -406M -355M -327M -303M -575M -38.73B -3.92B -1.54B -19.02B -1.52B -1.49B -65.87B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/07/26 | A$1.555 | +1.97% | 458,759 |
| 09/07/26 | A$1.525 | -2.24% | 385,986 |
| 08/07/26 | A$1.560 | +1.63% | 988,931 |
| 07/07/26 | A$1.535 | -1.29% | 731,828 |
| 06/07/26 | A$1.555 | +1.30% | 592,828 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PYC Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
